source
- Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competitionRevolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…
- Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancerMerck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…